Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
5 Results for "
p53-deficient cancers
" in MedChemExpress (MCE) Product Catalog:
Products (5)
5 Results for "p53-deficient cancers" in MCE Product Catalog:
1
1 Cited Publications
Target:
Research Areas:
M47 is a molecular glue that selectively destabilizes Cryptochrome 1 (CRY1) and increases degradation of the CRY1 in the nucleus. M47 enhances apoptosis in Ras-transformed P53-deficient mouse skin fibroblast lines and enhances life span in p53 knockout mice. M47 can be used in research of cancer .
Cat. No.: HY-123739
CAS No.: 337500-87-5
LDN-0028574 is a PAK3 inhibitor. LDN-0028574 can be used in the research of p53-deficient cancers .
Cat. No.: HY-181440
CAS No.: 3092641-80-7
Target:
Research Areas:
TDG-IN-1 is an orally active, selective small-molecule inhibitor of thymine DNA glycosylase (TDG) with a Ka of 1.46 nM. TDG-IN-1 impairs the DNA-binding ability of TDG, induces downregulated expression of DHX9, accumulation of double-stranded RNA, and activation of the RIG-I/MDA5-MAVS pathway, while acting as a tumor suppressor, innate immune activator and immunostimulant. TDG-IN-1 inhibits the growth of p53-deficient tumor cells and xenograft tumors, and exerts a synthetic lethal effect with p53. TDG-IN-1 is applicable to the research of p53-deficient cancers .
Cat. No.: HY-179506
P53 Activator 16 (Compound JC16) is a p53 activator. P53 Activator 16 exhibits selective cytotoxicity and pro-apoptotic (apoptosis) activity towards p53-Y220C mutant cancer cells, while having little effect on wild-type or P53-deficient cells. P53 Activator 16 induces the conformational transition of cell p53-Y220C from the mutant form to the wild-type form, accompanied by the transcriptional activation of p53 target genes, without increasing the overall level of p53 protein. P53 Activator 16 can be used for the study of p53 mutant cancers .
Cat. No.: HY-118606
CAS No.: 296246-47-4
LDN-0044878 is a PAK3 inhibitor. LDN-0044878 inhibits the proliferation or induces the death of p53-deficient cells. LDN-0044878 exhibits moderate trypanocidal activity against Trypanosoma brucei, but does not directly inhibit the core target Rhodesain. LDN-0044878 can be used in studies related to cervical adenocarcinoma and Trypanosoma brucei infection.
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
